Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04574596 · ClinicalTrials.gov registry record

Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia Coli

A clinical trial, sponsored by Duke University.

Completed
Registry status
300
Enrollment target

NCT04574596: Completed study, sponsored by Duke University.

NCT04574596 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 300 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04574596 has completed, sponsored by Duke University.

COMPLETED
Registry status
300 participants
Enrollment target

Study Summary

This is a prospective, observational, multicenter, case-control study.

Primary Outcome

Number of participants who received oral-step down therapy for treatment of e. Coli

Interventions

  • OTHER no Intervention

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2020-11-12
Est. Completion 2021-06-01
Duke University

1,725 total trials

What the finished NCT04574596 record still lists

NCT04574596 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 1 intervention - of which no Intervention is the first listed.

NCT04574596 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04574596 about?

NCT04574596 is a clinical study titled "Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia Coli". This is a prospective, observational, multicenter, case-control study.

What is the current status of trial NCT04574596?

This trial is currently completed. The enrollment target is 300 participants. The study started on 2020-11-12. Estimated completion is 2021-06-01.

What interventions are being tested in trial NCT04574596?

The interventions under investigation include: no Intervention (OTHER).

Who is sponsoring clinical trial NCT04574596?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04574596, the US trial registry maintained by the National Library of Medicine. NCT04574596 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.